ClinicalTrials.gg
CompletedNCT05739695Updated Oct 28, 2026

A Trial of Radial EBUS Versus VBN for the Peripheral Pulmonary Lesions

An interventional study of Virtual bronchoscopy navigation and radial EBUS in Lung Cancer, Tuberculosis and Pneumonia, sponsored by Ilya Sivokozov. Completed at 6 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Ilya Sivokozov · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Lung Neoplasms with a site in Russia — 3 open to participants now, 11 under way, 4 of them phase 3. Lung Neoplasms · Russia.

Enrollment
10th of 19
118 · median 118
Started
2022
the only one that year
No phase
Only one
of the 20
Registered
13th of 20
by date
Lead sponsor
1 of 20
Ilya Sivokozov

Among the 20 studies in Lung Neoplasms with a site in Russia, this one is the 10th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is the only one with no phase, and was the 13th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

3 of the 20 studies in Lung Neoplasms with a site in Russia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lung Neoplasms with a site in Russia, or all of them as a file.
02

Study summary

Peripheral pulmonary lesions are of growing importance in respiratory field. Early detection of lung cancer, tuberculosis and other diseases often needs a bronchoscopic investigation with different types of navigation. Current randomized clinical study is intended to compare three different modalities of navigation in bronchial tree - virtual bronchoscopy (VBN), radial endobronchial ultrasound (EBUS) and combination of both techniques.

Read the detailed description

Current randomized clinical study is intended to compare three different modalities of navigation in bronchial tree - virtual bronchoscopy, radial EBUS and combination of both techniques. Around 300 patients with incidentally detected peripheral pulmonary lesions will be enrolled in 9 centers among Russia. All patients after obtaining an informed consent will be randomized in 1:1:1 fashion to three study groups depending on type of navigation technique used. All patients will undergone navigational bronchoscopy with rEBUS (group A), VBN (group B) and rEBUS+VBN (group C), data on diagnostic efficacy and safety of each modality of navigation will be analyzed.

03

Conditions studied

  • Lung Cancer
  • Tuberculosis
  • Pneumonia

Keywords

  • navigation bronchoscopy
  • virtual bronchoscopy navigation
  • radial endobronchial ultrasound
  • BAL
  • TBLB
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with newly diagnosed unverified solitary or multiple (up to 3) peripheral pulmonary lesions (PPLs)
  2. PPL size 5 - 40 mm
  3. Actual chest CT scan (\<31 days prior to navigation bronchoscopy), collimation 1 mm, pulmonary window, DICOM format
  4. Age > 18 years
  5. Signed form
  6. Willing and ability to undergone a navigational bronchoscopy

Exclusion criteria

Exclusion Criteria:

  1. Unability to undergone navigation bronchoscopy for any reason
  2. Any malignant disease during last 36 months
  3. Known central endobronchial lesion of any cause
  4. -infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    VBN

    Virtual bronchoscopy

    Diagnostic Test: Virtual bronchoscopy navigation

  • Experimental
    VBN+rEBUS

    Combination of VBN and radial EBUS

    Diagnostic Test: Virtual bronchoscopy navigation · Diagnostic Test: radial EBUS

  • Active comparator
    rEBUS

    Radial EBUS as a gold standard

    Diagnostic Test: radial EBUS

Interventions

  • Diagnostic testVirtual bronchoscopy navigation

    It is planned to use VBN as the only navigation technique to compare it with rEBUS

  • Diagnostic testradial EBUS

    It is planned to use rEBUS as the only navigation technique to compare it with VBN

06

What researchers measure

Primary outcomes

  1. Diagnostic Efficacy of navigational bronchoscopy in each study arm

    Incidence of final diagnoses confirmed by navigational bronchoscopy for each study arm

    Time frame: At the end of study enrollment

Secondary outcomes

  1. Efficacy of each endoscopic biopsy modality in confirmation of final diagnosis

    Incidence of final diagnoses confirmed by navigational bronchoscopy for bronchoalveolar lavage, brush and transbronchial lung biopsy separately

    Time frame: At the end of study enrollment

Other outcomes

  1. Safety profile of each study arm

    Incidence of complications reported at each study arm procedures

    Time frame: At the end of study enrollment

07

Study locations

6 sites
  • Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
    Chelyabinsk, Russia
  • Kurgan Regional Oncological Dispensary
    Kurgan, Russia
  • Central TB Research Institute
    Moscow, Russia
  • P. Hertsen Moscow Oncology Research Institute
    Moscow, Russia
  • National Medical Research Centre for Oncology
    Rostov-on-Don, Russia
  • Tomsk Regional Oncological Dispensary
    Tomsk, Russia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Jan 2024, 23 months.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 23 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2024 → Jan 2024 and completion Mar 2025 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2022
First posted
Feb 22, 2023
StartActual
Feb 1, 2022
Primary completionActual
Jan 1, 2024was Dec 2024
CompletionActual
Jun 1, 2025was Mar 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 28, 2026
Primary completion
Dec 1, 2024→Jan 1, 2024 (actual)
Oct 28, 2026
Study completion
Mar 1, 2025→Jun 1, 2025 (actual)
Oct 28, 2026
Enrollment
300 (estimated)→118 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Completed
    Primary completion Dec 1, 2024→Jan 1, 2024 (now actual)
    Study completion Mar 1, 2025→Jun 1, 2025 (now actual)
    Enrollment 300 (estimated)→118 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05739695
Lead sponsor
Ilya Sivokozov
Responsible party
Ilya Sivokozov (Head of Respiratory Endoscopy Department, Central TB Research Institute) — Sponsor-investigator
First posted
Feb 22, 2023
Start date
Feb 1, 2022
Primary completion
Jan 1, 2024
Completion
Jun 1, 2025
Last update
Oct 28, 2026

Study contacts

Ilya Sivokozov, MD PhD
study chair · Central TB Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion